Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Edgewise Therapeutics has sold its muscular dystrophy business to Servier for up to $2.65 billion, receiving an immediate $1.55 billion upfront payment. The transaction transfers the rights to sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies, along with the associated expert team.
Key figures
- Drug Name
- sevasemten
- Deal Value Usd
- 2650000000
- Upfront payment
- 1550000000
- Milestone payments
- 1100000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.